Report of Foreign Issuer (6-k)
July 18 2016 - 11:05AM
Edgar (US Regulatory)
United
States
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
OF THE SECURITIES EXCHANGE ACT OF 1934
For the Month of July, 2016
Commission File Number: 001-35892
GW PHARMACEUTICALS PLC
(Translation of registrant’s name
into English)
Sovereign House
Vision Park
Histon
Cambridge CB24 9BZ
United Kingdom
(Address of principal executive offices)
Indicate by check mark whether the registrant
files or will file annual reports under cover of Form 20-F or Form 40-F.
Indicate by check mark if the registrant
is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):
Indicate by check mark if the registrant
is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):
Other Events
On July 18, 2016, GW Pharmaceuticals plc
(the “Company”) announced the closing of the previously announced offering on the NASDAQ Global Market by the Company
of 2,800,000 American Depositary Shares (“ADSs”) and the full exercise by the underwriters of their option to purchase
420,000 additional ADSs from the Company at a price of $90.00 per ADS, raising gross proceeds of approximately $289.8 million (before
deducting underwriting discounts, commissions and offering expenses). The press release attached as Exhibit 99.1 is furnished and
incorporated by reference herein.
Exhibits
99.1 Press Release dated July 18, 2016
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly
authorized.
|
GW Pharmaceuticals plc
|
|
|
|
|
By:
|
/s/ Adam George
|
|
Name:
|
Adam George
|
|
Title:
|
Chief Financial Officer
|
|
|
|
Date: July 18, 2016
|
|
|